AIM: Cytidine deaminase (CDA) irreversibly deaminates cytarabine (Ara-C), a key component of acute myeloid leukemia (AML) induction and consolidation therapy. CDA overexpression results in Ara-C resistance, while decreased expression is associated with toxicity. We evaluated factors influencing variation in CDA mRNA expression in adult AML patients and normal controls, and how they contributed to Ara-C cytotoxicity in AML cells. MATERIALS & METHODS: CDA mRNA expression in 100 de novo AML patients and 36 normal controls were determined using quantitative reverse-transcriptase PCR. Genetic variants in the CDA gene were screened by direct sequencing. IC₅₀ of Ara-C was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. RESULTS: CDA RNA expression as well as Ara-C IC₅₀ showed wide variation in AML samples and normal controls. Fourteen sequence variants were identified, three of which (-33delC, intron 2 TCAT repeat and the 3´untranslated region 816delC variants) showed significant association with RNA expression and the nonsynonymous coding variant 79A>C was associated with Ara-C cytotoxicity. CONCLUSION: CDA genetic variants explain the variation in RNA expression and may be candidates for individualizing Ara-C therapy.
AIM: Cytidine deaminase (CDA) irreversibly deaminates cytarabine (Ara-C), a key component of acute myeloid leukemia (AML) induction and consolidation therapy. CDA overexpression results in Ara-C resistance, while decreased expression is associated with toxicity. We evaluated factors influencing variation in CDA mRNA expression in adult AMLpatients and normal controls, and how they contributed to Ara-Ccytotoxicity in AML cells. MATERIALS & METHODS:CDA mRNA expression in 100 de novo AMLpatients and 36 normal controls were determined using quantitative reverse-transcriptase PCR. Genetic variants in the CDA gene were screened by direct sequencing. IC₅₀ of Ara-C was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. RESULTS:CDA RNA expression as well as Ara-C IC₅₀ showed wide variation in AML samples and normal controls. Fourteen sequence variants were identified, three of which (-33delC, intron 2 TCAT repeat and the 3´untranslated region 816delC variants) showed significant association with RNA expression and the nonsynonymous coding variant 79A>C was associated with Ara-Ccytotoxicity. CONCLUSION:CDA genetic variants explain the variation in RNA expression and may be candidates for individualizing Ara-C therapy.
Authors: Danielle Malheiros; Rodrigo A Panepucci; Ana M Roselino; Amélia G Araújo; Marco A Zago; Maria Luiza Petzl-Erler Journal: Immunology Date: 2014-11 Impact factor: 7.397
Authors: Hamza Mameri; Ivan Bièche; Didier Meseure; Elisabetta Marangoni; Géraldine Buhagiar-Labarchède; André Nicolas; Sophie Vacher; Rosine Onclercq-Delic; Vinodh Rajapakse; Sudhir Varma; William C Reinhold; Yves Pommier; Mounira Amor-Guéret Journal: Clin Cancer Res Date: 2016-09-06 Impact factor: 12.531
Authors: Abdelrahman H Elsayed; Xueyuan Cao; Kristine R Crews; Varsha Gandhi; William Plunkett; Jeffrey E Rubnitz; Raul C Ribeiro; Stanley B Pounds; Jatinder K Lamba Journal: Pharmacogenomics Date: 2018-08-08 Impact factor: 2.533
Authors: Lillian Sung; Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Wang; Soheil Meshinchi; Alan S Gamis Journal: Int J Cancer Date: 2016-07-04 Impact factor: 7.396